Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2001 May;109(5):539–545. doi: 10.1289/ehp.01109539

Possible estuary-associated syndrome: symptoms, vision, and treatment.

R C Shoemaker 1, H K Hudnell 1
PMCID: PMC1240316  PMID: 11401768

Abstract

The human illness designated as possible estuarine-associated syndrome (PEAS) by the Centers for Disease Control and Prevention (CDC) has been associated with exposure to estuaries inhabited by toxin-forming dinoflagellates, including members of the fish-killing toxic Pfiesteria complex (TPC), Pfiesteria piscicida and Pfiesteria shumwayae. Humans may be exposed through direct contact with estuarine water or by inhalation of aerosolized or volatilized toxin(s). The five cases reported here demonstrate the full spectrum of symptoms experienced during acute and chronic stages of this suspected neurotoxin-mediated illness. The nonspecific symptoms most commonly reported are cough, secretory diarrhea, headache, fatigue, memory impairment, rash, difficulty in concentrating, light sensitivity, burning skin upon water contact, muscle ache, and abdominal pain. Less frequently encountered symptoms are upper airway obstruction, shortness of breath, confusion, red or tearing eyes, weakness, and vertigo. Some patients experience as few as four of these symptoms. The discovery that an indicator of visual pattern-detection ability, visual contrast sensitivity (VCS), is sharply reduced in affected individuals has provided an objective indicator that is useful in diagnosing and monitoring PEAS. VCS deficits are present in both acute and chronic PEAS, and VCS recovers during cholestyramine treatment coincident with symptom abatement. Although PEAS cannot yet be definitively associated with TPC exposure, resolution with cholestyramine treatment suggests a neurotoxin-mediated illness.

Full Text

The Full Text of this article is available as a PDF (101.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen T., Andersen J. R., Tvede M., Franzmann M. B. Collagenous colitis: are bacterial cytotoxins responsible? Am J Gastroenterol. 1993 Mar;88(3):375–377. [PubMed] [Google Scholar]
  2. Boylan J. J., Egle J. L., Guzelian P. S. Cholestyramine: use as a new therapeutic approach for chlordecone (kepone) poisoning. Science. 1978 Feb 24;199(4331):893–895. doi: 10.1126/science.74852. [DOI] [PubMed] [Google Scholar]
  3. Brouillard M. Y., Rateau J. G. La cholestyramine fixe les toxines d'Escherichia coli et de Vibrio cholerae par une liaison ionique. Ann Gastroenterol Hepatol (Paris) 1990 Jan-Feb;26(1):27–30. [PubMed] [Google Scholar]
  4. Bungay P. M., Dedrick R. L., Matthews H. B. Pharmacokinetics of halogenated hydrocarbons. Ann N Y Acad Sci. 1979 May 31;320:257–270. doi: 10.1111/j.1749-6632.1979.tb56607.x. [DOI] [PubMed] [Google Scholar]
  5. Burkholder J. M., Noga E. J., Hobbs C. H., Glasgow H. B., Jr, Smith S. A. New 'phantom' dinoflagellate is the causative agent of major estuarine fish kills. Nature. 1992 Jul 30;358(6385):407–410. doi: 10.1038/358407a0. [DOI] [PubMed] [Google Scholar]
  6. Cohn W. J., Boylan J. J., Blanke R. V., Fariss M. W., Howell J. R., Guzelian P. S. Treatment of chlordecone (Kepone) toxicity with cholestyramine. Results of a controlled clinical trial. N Engl J Med. 1978 Feb 2;298(5):243–248. doi: 10.1056/NEJM197802022980504. [DOI] [PubMed] [Google Scholar]
  7. Creppy E. E., Baudrimont I., Betbeder A. M. Prevention of nephrotoxicity of ochratoxin A, a food contaminant. Toxicol Lett. 1995 Dec;82-83:869–877. doi: 10.1016/0378-4274(95)03601-6. [DOI] [PubMed] [Google Scholar]
  8. Dahlem A. M., Hassan A. S., Swanson S. P., Carmichael W. W., Beasley V. R. A model system for studying the bioavailability of intestinally administered microcystin-LR, a hepatotoxic peptide from the cyanobacterium Microcystis aeruginosa. Pharmacol Toxicol. 1989 Feb;64(2):177–181. doi: 10.1111/j.1600-0773.1989.tb00625.x. [DOI] [PubMed] [Google Scholar]
  9. El-Nabawi A., Quesenberry M., Saito K., Silbergeld E., Vasta G., Eldefrawi A. The N-methyl-D-aspartate neurotransmitter receptor is a mammalian brain target for the dinoflagellate Pfiesteria piscicida toxin. Toxicol Appl Pharmacol. 2000 Nov 15;169(1):84–93. doi: 10.1006/taap.2000.9042. [DOI] [PubMed] [Google Scholar]
  10. Fairey E. R., Edmunds J. S., Deamer-Melia N. J., Glasgow H., Jr, Johnson F. M., Moeller P. R., Burkholder J. M., Ramsdell J. S. Reporter gene assay for fish-killing activity produced by Pfiesteria piscicida. Environ Health Perspect. 1999 Sep;107(9):711–714. doi: 10.1289/ehp.99107711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ginsburg A. P. A new contrast sensitivity vision test chart. Am J Optom Physiol Opt. 1984 Jun;61(6):403–407. doi: 10.1097/00006324-198406000-00011. [DOI] [PubMed] [Google Scholar]
  12. Ginsburg A. P., Evans D. W., Cannon M. W., Jr, Owsley C., Mulvanny P. Large-sample norms for contrast sensitivity. Am J Optom Physiol Opt. 1984 Feb;61(2):80–84. doi: 10.1097/00006324-198402000-00003. [DOI] [PubMed] [Google Scholar]
  13. Glasgow H. B., Jr, Burkholder J. M., Schmechel D. E., Tester P. A., Rublee P. A. Insidious effects of a toxic estuarine dinoflagellate on fish survival and human health. J Toxicol Environ Health. 1995 Dec;46(4):501–522. doi: 10.1080/15287399509532051. [DOI] [PubMed] [Google Scholar]
  14. Grattan L. M., Oldach D., Perl T. M., Lowitt M. H., Matuszak D. L., Dickson C., Parrott C., Shoemaker R. C., Kauffman C. L., Wasserman M. P. Learning and memory difficulties after environmental exposure to waterways containing toxin-producing Pfiesteria or Pfiesteria-like dinoflagellates. Lancet. 1998 Aug 15;352(9127):532–539. doi: 10.1016/S0140-6736(98)02132-1. [DOI] [PubMed] [Google Scholar]
  15. Hudnell H. K., Otto D. A., House D. E. The influence of vision on computerized neurobehavioral test scores: a proposal for improving test protocols. Neurotoxicol Teratol. 1996 Jul-Aug;18(4):391–400. doi: 10.1016/0892-0362(96)00040-2. [DOI] [PubMed] [Google Scholar]
  16. Hudnell H. K., Skalik I., Otto D., House D., Subrt P., Sram R. Visual contrast sensitivity deficits in Bohemian children. Neurotoxicology. 1996 Fall-Winter;17(3-4):615–628. [PubMed] [Google Scholar]
  17. Humphrey C. D., Condon C. W., Cantey J. R., Pittman F. E. Partial purification of a toxin found in hamsters with antibiotic-associated colitis. Reversible binding of the toxin by cholestyramine. Gastroenterology. 1979 Mar;76(3):468–476. [PubMed] [Google Scholar]
  18. Kerkadi A., Barriault C., Tuchweber B., Frohlich A. A., Marquardt R. R., Bouchard G., Yousef I. M. Dietary cholestyramine reduces ochratoxin A-induced nephrotoxicity in the rat by decreasing plasma levels and enhancing fecal excretion of the toxin. J Toxicol Environ Health A. 1998 Feb 6;53(3):231–250. doi: 10.1080/009841098159367. [DOI] [PubMed] [Google Scholar]
  19. Lewis R. J., Sellin M., Poli M. A., Norton R. S., MacLeod J. K., Sheil M. M. Purification and characterization of ciguatoxins from moray eel (Lycodontis javanicus, Muraenidae). Toxicon. 1991;29(9):1115–1127. doi: 10.1016/0041-0101(91)90209-a. [DOI] [PubMed] [Google Scholar]
  20. Liacouras C. A., Piccoli D. A. Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis. J Clin Gastroenterol. 1996 Apr;22(3):186–189. doi: 10.1097/00004836-199604000-00007. [DOI] [PubMed] [Google Scholar]
  21. Livingstone M., Hubel D. Segregation of form, color, movement, and depth: anatomy, physiology, and perception. Science. 1988 May 6;240(4853):740–749. doi: 10.1126/science.3283936. [DOI] [PubMed] [Google Scholar]
  22. Moncino M. D., Falletta J. M. Multiple relapses of Clostridium difficile-associated diarrhea in a cancer patient. Successful control with long-term cholestyramine therapy. Am J Pediatr Hematol Oncol. 1992 Nov;14(4):361–364. [PubMed] [Google Scholar]
  23. Mutter L. C., Blanke R. V., Jandacek R. J., Guzelian P. S. Reduction in the body content of DDE in the Mongolian gerbil treated with sucrose polyester and caloric restriction. Toxicol Appl Pharmacol. 1988 Mar 15;92(3):428–435. doi: 10.1016/0041-008x(88)90182-2. [DOI] [PubMed] [Google Scholar]
  24. Oldach D. W., Delwiche C. F., Jakobsen K. S., Tengs T., Brown E. G., Kempton J. W., Schaefer E. F., Bowers H. A., Glasgow H. B., Jr, Burkholder J. M. Heteroduplex mobility assay-guided sequence discovery: elucidation of the small subunit (18S) rDNA sequences of Pfiesteria piscicida and related dinoflagellates from complex algal culture and environmental sample DNA pools. Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4303–4308. doi: 10.1073/pnas.97.8.4303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rateau J. G., Brouillard M., Morgant G., Aymard P. Etude expérimentale chez le lapin de l'effet de la cholestyramine dans le traitement des diarrhées infectieuses d'origine cholérique. Ann Gastroenterol Hepatol (Paris) 1986 Oct;22(5):289–296. [PubMed] [Google Scholar]
  26. Shoemaker R. C. Diagnosis of Pfiesteria-human illness syndrome. Md Med J. 1997 Nov-Dec;46(10):521–523. [PubMed] [Google Scholar]
  27. Shoemaker R. Treatment of persistent Pfiesteria-human illness syndrome. Md Med J. 1998 Feb-Mar;47(2):64–66. [PubMed] [Google Scholar]
  28. Underhill K. L., Rotter B. A., Thompson B. K., Prelusky D. B., Trenholm H. L. Effectiveness of cholestyramine in the detoxification of zearalenone as determined in mice. Bull Environ Contam Toxicol. 1995 Jan;54(1):128–134. doi: 10.1007/BF00196279. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES